New drug miricorilant tested for fatty liver disease safety
NCT ID NCT07553663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, but rather a first step to gather important safety information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- miricorilant
- What this could lead to
- If successful, this study could provide early safety data to support larger trials of miricorilant for MASH.
- What could go wrong
- This is a very early, small Phase 1b study with only 15 participants, focused on safety and drug levels—not on whether the drug works. It may not lead to an effective treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site# 433
RECRUITINGSan Antonio, Texas, 78215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single pill tackle both fatty liver and diabetes?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- 10-Year quest to uncover fatty Liver's hidden toll in china
- Navy beans take on fatty liver: a diet swap put to the test
- Can a promising NAFLD drug safely mix with other medicines? a trial seeks answers
- New ultrasound device could replace costly MRI for liver disease detection